Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Dayton
704
mi
from 02139
Dayton, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Dayton
704
mi
from 02139
Dayton, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Blanchard Valley Medical Associates
652
mi
from 02139
Findlay, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Blanchard Valley Medical Associates
652
mi
from 02139
Findlay, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Charles F. Kettering Memorial Hospital
704
mi
from 02139
Kettering, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Charles F. Kettering Memorial Hospital
704
mi
from 02139
Kettering, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Middletown Regional Hospital
720
mi
from 02139
Middletown, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Middletown Regional Hospital
720
mi
from 02139
Middletown, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
UVMC Cancer Care Center at Upper Valley Medical Center
699
mi
from 02139
Troy, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
UVMC Cancer Care Center at Upper Valley Medical Center
699
mi
from 02139
Troy, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
United States Air Force Medical Center - Wright-Patterson
mi
from 02139
Wright-Patterson Air Force Base, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
United States Air Force Medical Center - Wright-Patterson
mi
from 02139
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
692
mi
from 02139
Xenia, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
692
mi
from 02139
Xenia, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Tod Children's Hospital - Forum Health
499
mi
from 02139
Youngstown, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Tod Children's Hospital - Forum Health
499
mi
from 02139
Youngstown, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Legacy Mount Hood Medical Center
2519
mi
from 02139
Gresham, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Legacy Mount Hood Medical Center
2519
mi
from 02139
Gresham, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Providence Milwaukie Hospital
2529
mi
from 02139
Milwaukie, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Providence Milwaukie Hospital
2529
mi
from 02139
Milwaukie, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center
2532
mi
from 02139
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center
2532
mi
from 02139
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Providence Cancer Center at Providence Portland Medical Center
2526
mi
from 02139
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Center at Providence Portland Medical Center
2526
mi
from 02139
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Columbia River Oncology Program
2535
mi
from 02139
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Columbia River Oncology Program
2535
mi
from 02139
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Providence St. Vincent Medical Center
2535
mi
from 02139
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Providence St. Vincent Medical Center
2535
mi
from 02139
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Legacy Emanuel Hospital and Health Center & Children's Hospital
2530
mi
from 02139
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Legacy Emanuel Hospital and Health Center & Children's Hospital
2530
mi
from 02139
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Oregon Health & Science University Cancer Institute
2531
mi
from 02139
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Oregon Health & Science University Cancer Institute
2531
mi
from 02139
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Salem Hospital Regional Cancer Care Services
2529
mi
from 02139
Salem, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Salem Hospital Regional Cancer Care Services
2529
mi
from 02139
Salem, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Legacy Meridian Park Hospital
2537
mi
from 02139
Tualatin, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Legacy Meridian Park Hospital
2537
mi
from 02139
Tualatin, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
AnMedical Health Cancer Center
824
mi
from 02139
Anderson, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
AnMedical Health Cancer Center
824
mi
from 02139
Anderson, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Hollings Cancer Center at Medical University of South Carolina
819
mi
from 02139
Charleston, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Hollings Cancer Center at Medical University of South Carolina
819
mi
from 02139
Charleston, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Bon Secours St. Francis Health System
801
mi
from 02139
Greenville, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Bon Secours St. Francis Health System
801
mi
from 02139
Greenville, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Greenville
795
mi
from 02139
Greenville, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Greenville
795
mi
from 02139
Greenville, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Upstate Carolina
775
mi
from 02139
Spartanburg, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Upstate Carolina
775
mi
from 02139
Spartanburg, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
775
mi
from 02139
Spartanburg, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
775
mi
from 02139
Spartanburg, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Brooke Army Medical Center
1759
mi
from 02139
Fort Sam Houston, TX
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Brooke Army Medical Center
1759
mi
from 02139
Fort Sam Houston, TX
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Wilford Hall Medical Center
1770
mi
from 02139
Lackland Air Force Base, TX
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Wilford Hall Medical Center
1770
mi
from 02139
Lackland Air Force Base, TX
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Scott and White Hospital
1640
mi
from 02139
Temple, TX
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Scott and White Hospital
1640
mi
from 02139
Temple, TX
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Danville Regional Medical Center
597
mi
from 02139
Danville, VA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Danville Regional Medical Center
597
mi
from 02139
Danville, VA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
St. Joseph Cancer Center
2476
mi
from 02139
Bellingham, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
St. Joseph Cancer Center
2476
mi
from 02139
Bellingham, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Olympic Hematology and Oncology
2497
mi
from 02139
Bremerton, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Olympic Hematology and Oncology
2497
mi
from 02139
Bremerton, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Skagit Valley Hospital Cancer Care Center
2472
mi
from 02139
Mount Vernon, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Skagit Valley Hospital Cancer Care Center
2472
mi
from 02139
Mount Vernon, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
2482
mi
from 02139
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
2482
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Harborview Medical Center
2483
mi
from 02139
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Harborview Medical Center
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Minor and James Medical, PLLC
2483
mi
from 02139
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Minor and James Medical, PLLC
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Group Health Capitol Hill Campus
2482
mi
from 02139
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Group Health Capitol Hill Campus
2482
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
2482
mi
from 02139
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
2482
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Polyclinic First Hill
2481
mi
from 02139
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Polyclinic First Hill
2481
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
University Cancer Center at University of Washington Medical Center
2461
mi
from 02139
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
University Cancer Center at University of Washington Medical Center
2461
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
North Puget Oncology at United General Hospital
2467
mi
from 02139
Sedro-Woolley, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
North Puget Oncology at United General Hospital
2467
mi
from 02139
Sedro-Woolley, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Care Northwest - Spokane South
2256
mi
from 02139
Spokane, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Care Northwest - Spokane South
2256
mi
from 02139
Spokane, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Southwest Washington Medical Center Cancer Center
2518
mi
from 02139
Vancouver, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Southwest Washington Medical Center Cancer Center
2518
mi
from 02139
Vancouver, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Wenatchee Valley Medical Center
2393
mi
from 02139
Wenatchee, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Wenatchee Valley Medical Center
2393
mi
from 02139
Wenatchee, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
North Star Lodge
2414
mi
from 02139
Yakima, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
North Star Lodge
2414
mi
from 02139
Yakima, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
1787
mi
from 02139
Sheridan, WY
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
1787
mi
from 02139
Sheridan, WY
Click here to add this to my saved trials
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
HealthAlliance Hospitals
mi
from 02139
Fitchburg, MA
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
HealthAlliance Hospitals
mi
from 02139
Fitchburg, MA
Click here to add this to my saved trials
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
105
mi
from 02139
Lebanon, NH
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
105
mi
from 02139
Lebanon, NH
Click here to add this to my saved trials
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Albert Einstein Cancer Center
176
mi
from 02139
Bronx, NY
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Albert Einstein Cancer Center
176
mi
from 02139
Bronx, NY
Click here to add this to my saved trials
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Jacobi Medical Center
176
mi
from 02139
Bronx, NY
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Jacobi Medical Center
176
mi
from 02139
Bronx, NY
Click here to add this to my saved trials
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
176
mi
from 02139
Bronx, NY
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
176
mi
from 02139
Bronx, NY
Click here to add this to my saved trials
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance
Quality of Life in Younger Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Community Hospital of the Monterey Peninsula Comprehensive Cancer Center
2697
mi
from 02139
Monterey, CA
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance
Quality of Life in Younger Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Community Hospital of the Monterey Peninsula Comprehensive Cancer Center
2697
mi
from 02139
Monterey, CA
Click here to add this to my saved trials